Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05397093 · ClinicalTrials.gov registry record · Phase 1
ITIL-306 in Advanced Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Renal Cell Carcinoma, sponsored by Instil Bio.
- Active
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 2
- Study locations
NCT05397093 is a Phase 1 study of Non-Small Cell Lung Cancer and Renal Cell Carcinoma that is active but no longer recruiting, run by Instil Bio. The registered enrollment target is 51 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05397093, a Phase 1 study of Non-Small Cell Lung Cancer and Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Instil Bio.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 2
- Study locations
Study Summary
ITIL-306-201 is a phase 1a/1b, multicenter, clinical trial evaluating the safety and feasibility of ITIL-306 in adult participants with advanced solid tumors whose disease has progressed after standard therapy. ITIL-306 is a cell therapy derived from a participant's own tumor-infiltrating immune cells (lymphocytes; TILs) and contains a unique molecule designed to increase TIL activity when it encounters folate receptor α (FOLR1) on the tumor.
Conditions Studied
Interventions
- BIOLOGICAL ITIL-306
Study Locations (2)
Missouri
- Washington University School of Medicine - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2039-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05397093
The ClinicalTrials.gov registry entry for NCT05397093 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Instil Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which ITIL-306 is the first listed.
NCT05397093 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT05397093 about?
NCT05397093 is a clinical study titled "ITIL-306 in Advanced Solid Tumors". ITIL-306-201 is a phase 1a/1b, multicenter, clinical trial evaluating the safety and feasibility of ITIL-306 in adult participants with advanced solid tumors whose disease has progressed after standard therapy. ITIL-306 is a cell therapy derived from a participant's own tumor-infiltrating immune cel...
What is the current status of trial NCT05397093?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2022-08-24. Estimated completion is 2039-11.
What conditions does trial NCT05397093 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Epithelial Ovarian Cancer.
What interventions are being tested in trial NCT05397093?
The interventions under investigation include: ITIL-306 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05397093?
This trial is sponsored by Instil Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05397093 being conducted?
This trial has 2 study locations across Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.